ArticleACS applied materials & interfaces2013
Triblock copolymer-encapsulated nanoparticles with outstanding colloidal stability for siRNA delivery.
Article in ACS applied materials & interfaces, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Meta-analysis of cellular toxicity for cadmium-containing quantum dots.Nature nanotechnology · 2016Pooled it
- Irinotecan-Loaded Polymeric Micelles as a Promising Alternative to Enhance Antitumor Efficacy in Colorectal Cancer Therapy.Polymers · 2022Article
- Optimization of Weight Ratio for DSPE-PEG/TPGS Hybrid Micelles to Improve Drug Retention and Tumor Penetration.Pharmaceutical research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
A new generation of siRNA nanocarrier with compact, uniform size and excellent colloidal stability has been developed by combining inorganic nanoparticles with rationally designed triblock copolymers. In contrast to conventional cationic polymers and nanoparticles that often condense oligonucleotides into polydisperse aggregates, our nanoparticle-polymer complexes remain single after loading with siRNA. More importantly, they are highly stable even in complete serum, which fills the gap between in vitro technology development using serum-free (or low percentage serum) cell culture media and downstream in vivo applications. Targeted delivery is achieved in GFP-expressing HeLa cells by functionalizing the siRNA delivery vehicle with an integrin-specific peptide ligand. The GFP positive cell population can be reduced from the original 86 to 60 and 25% for nontargeted and targeted nanoparticle-polymer complexes, respectively. At the nanocarrier concentration for siRNA delivery, virtually no cytotoxicity was detected. Further development and validation of this technology by introducing biodegradable and biocompatible core particles and testing them in lab animals could enable widespread uses of siRNA and potentially lead to clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.